Eli Lilly took to the stage at the American Society of Clinical Oncology meeting in Chicago to share early data for a new drug candidate that could, if all goes right, challenge the dominance of Pfizer and Astellas Pharma’s Padcev in bladder cancer.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Eli Lilly took to the stage at the American Society of Clinical Oncology meeting in Chicago to share early data for a new drug candidate that could, if all goes right, challenge the dominance of Pfizer and Astellas Pharma’s Padcev in bladder cancer.